Gary Nachman Analyst PerformanceManaging Director BioPharma/Biotechnology at Raymond James FinancialGary Nachman is a stock analyst at Raymond James Financial in the medical sector, covering 16 publicly traded companies. Over the past year, Gary Nachman has issued 25 stock ratings, including strong buy, buy, and hold recommendations. While full access to Gary Nachman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gary Nachman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings53 Last 9 YearsBuy Recommendations75.00% 39 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution52RatingsDistribution of strong buy, buy, hold, and sell ratings by Gary Nachman.RatingPercentageCount Strong Buy15.4%8 ratings Buy59.6%31 ratings Hold19.2%10 ratings Sell5.8%3 ratingsOut of 52 total stock ratings issued by Gary Nachman at Raymond James Financial, the majority (59.6%) have been Buy recommendations, followed by 19.2% Hold, 15.4% Strong Buy, and 5.8% Sell.Best & Worst CallsBest Call0000.0%SAGEJul 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%JAZZJul 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ81.3% of companies on NASDAQ13 companiesNYSE18.8% of companies on NYSE3 companiesGary Nachman, an analyst at Raymond James Financial, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical16 companies100.0%Gary Nachman of Raymond James Financial specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE9 companies56.3%MED - DRUGS2 companies12.5%LARGE CAP PHARMA1 company6.3%MEDICAL SERVICES1 company6.3%MED PRODUCTS1 company6.3%PHARMACEUTICAL PREPARATIONS1 company6.3%MED - GENERIC DRG1 company6.3% About Gary NachmanGary Nachman joined Raymond James in 2023 as a senior analyst covering biotechnology and specialty pharmaceuticals. Prior to joining the firm, he was most recently a managing director covering biopharma and specialty pharma at BMO Capital Markets for seven years. Before that, he was a senior analyst covering specialty pharma at Goldman Sachs, Susquehanna International Group, Leerink Swann and Morgan Stanley. Before getting into equity research, Gary spent a few years in the pharmaceutical industry at Merck, where he was a manager in the financial evaluations group at Merck‐Medco. Gary earned his MBA from Columbia Business School and a B.S. in accounting from Binghamton University, where he graduated magna cum laude.Follow on LinkedIn Gary Nachman's Ratings History at Raymond James Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsADMAADMA Biologics5/7/2026Lower Price Target$10.08$18.00Buy$0.0000.00% ROIABBVAbbVie4/30/2026Boost Price Target$211.66$265.00Buy$0.0000.00% ROIABBVAbbVie4/20/2026Initiated Coverage$204.08$262.00Buy$0.0000.00% ROISRRKScholar Rock4/20/2026Initiated Coverage$47.80$62.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/20/2026Initiated Coverage$74.87$110.00Buy$0.0000.00% ROIADMAADMA Biologics4/20/2026Initiated Coverage$10.88$21.00Buy$0.0000.00% ROIACHVAchieve Life Sciences4/20/2026Set Price Target$4.25$13.00Buy$0.0000.00% ROIAMGNAmgen4/20/2026Initiated Coverage$350.16$366.00Hold$0.0000.00% ROIABBVAbbVie4/20/2026Upgrade$204.95Strong-Buy$0.0000.00% ROIACHVAchieve Life Sciences4/20/2026Upgrade$4.21Strong-Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ADMAADMA Biologics4/20/2026Upgrade$10.78Strong-Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/20/2026Upgrade$74.78Strong-Buy$0.0000.00% ROISRRKScholar Rock4/20/2026Upgrade$48.10Strong-Buy$0.0000.00% ROIABBVAbbVie11/3/2025Set Price Target$218.14$256.00$0.0000.00% ROIBLCOBausch + Lomb10/30/2025Reiterated Rating$15.39$19.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals10/30/2025Reiterated Rating$73.57$89.00Strong-Buy$0.0000.00% ROILENZLENZ Therapeutics10/20/2025Reiterated Rating$36.63$50.00Outperform$0.0000.00% ROIABBVAbbVie10/17/2025Reiterated Rating$226.77$250.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals9/22/2025Set Price Target$61.36$75.00Strong-Buy$0.0000.00% ROIAMGNAmgen9/3/2025Initiated Coverage$286.07Market Perform$0.0000.00% ROIABBVAbbVie8/25/2025Reiterated Rating$207.74Outperform$0.0000.00% ROIVERUVeru8/13/2025Lower Price Target$3.17$20.00Outperform$0.0000.00% ROIABBVAbbVie8/1/2025Boost Price Target$189.02$236.00Outperform$0.0000.00% ROILENZLENZ Therapeutics7/31/2025Boost Price Target$30.98$40.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals7/31/2025Boost Price Target$43.35$64.00Strong-Buy$0.0000.00% ROIABBVAbbVie2/3/2025Reiterated Rating$183.90$220.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
